VHB937 

VHB937 is a potent and selective TREM2 agonist, a human monoclonal antibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research^[1].

VHB937 increases Syk-phosphorylation and drives calcium signaling in human primary cells with endogenous TREM2 expression^[1].
VHB937 facilitates key functions of microglia cells like chemotaxis and phagocytosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

VHB937 promotes neuronal health and ameliorates astrogliosis in diverse neurodegenerative disease animal models, through the induction of a neuroprotective microglial phenotype, demonstrating its efficacy beyond microglia^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

54209  [NCBI]

Q9NZC2

TREM-2

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Stangel M, et al. VHB937, a TREM2 stabilizing and activating antibody strongly reduces pathology after peripheral administration in a broad range of animal models for neuroinflammation and neurodegeneration (P4-4.004). Neurology. 2024;102(7_supplement_1).